Risk factors associated with in-hospital complications for pediatric sickle-cell disease-associated moyamoya syndrome: a nationwide cross-sectional study

Scott RM, Smith ER (2009) Moyamoya disease and moyamoya syndrome. 360:1226–1237. https://doi.org/10.1056/NEJMRA0804622

McCrea N, Fullerton HJ, Ganesan V (2019) Genetic and environmental associations with pediatric cerebral arteriopathy. Stroke 50:257–265. https://doi.org/10.1161/STROKEAHA.118.020479

Fullerton HJ, Wintermark M, Hills NK, Dowling MM, Tan M, Rafay MF et al (2016) Risk of Recurrent arterial ischemic stroke in childhood: a prospective international study. Stroke 47:53–59. https://doi.org/10.1161/STROKEAHA.115.011173

Ghaffari-Rafi A, Ghaffari-Rafi S, Leon-Rojas J (2020) Socioeconomic and demographic disparities of moyamoya disease in the United States. Clin Neurol Neurosurg 192. https://doi.org/10.1016/J.CLINEURO.2020.105719

Kuriyama S, Kusaka Y, Fujimura M, Wakai K, Tamakoshi A, Hashimoto S et al (2008) Prevalence and clinicoepidemiological features of moyamoya disease in Japan: findings from a nationwide epidemiological survey. Stroke 39:42–47. https://doi.org/10.1161/STROKEAHA.107.490714

Uchino K, Johnston SC, Becker KJ, Tirschwell DL (2005) Moyamoya disease in Washington State and California. Neurology 65:956–958. https://doi.org/10.1212/01.WNL.0000176066.33797.82

Wakai K, Tamakoshi A, Ikezaki K, Fukui M, Kawamura T, Aoki R et al (1997) Epidemiological features of moyamoya disease in Japan: findings from a nationwide survey. Clin Neurol Neurosurg 99(Suppl):2. https://doi.org/10.1016/S0303-8467(97)00031-0

Farooq S, Testai FD (2019) Neurologic complications of sickle cell disease. Curr Neurol Neurosci Rep 19:1–8. https://doi.org/10.1007/S11910-019-0932-0/TABLES/2

Dobson SR, Holden KR, Nietert PJ, Cure JK, Laver JH, Disco D et al (2002) Moyamoya syndrome in childhood sickle cell disease: a predictive factor for recurrent cerebrovascular events. Blood 99:3144–3150. https://doi.org/10.1182/BLOOD.V99.9.3144

Aguilar-Salinas P, Hayward K, Santos R, Agarwal V, Sauvageau E, Hanel RA et al (2019) Surgical revascularization for pediatric patients with sickle cell disease and moyamoya disease in the prevention of ischemic strokes: a single-center case series and a systematic review. World Neurosurgery 123:435-442.e8. https://doi.org/10.1016/J.WNEU.2018.11.157

DeBaun MR, Jordan LC, King AA, Schatz J, Vichinsky E, Fox CK et al (2020) American Society of Hematology 2020 guidelines for sickle cell disease: prevention, diagnosis, and treatment of cerebrovascular disease in children and adults. Blood Adv 4:1554–1588. https://doi.org/10.1182/bloodadvances.2019001142

Fryer RH, Anderson RC, Chiriboga CA, Feldstein NA (2003) Sickle cell anemia with moyamoya disease: outcomes after EDAS procedure. Pediatr Neurol 29:124–130. https://doi.org/10.1016/S0887-8994(03)00047-X

Newman S, Boulter JH, Malcolm JG, Pradilla I, Pradilla G (2020) Outcomes in patients with moyamoya syndrome and sickle cell disease: a systematic review. World Neurosurgery 135:165–170. https://doi.org/10.1016/J.WNEU.2019.11.137

Newman S, McMahon JT, Boulter JH, Malcolm JG, Revuelta Barbero JM, Chern JJ et al (2022) Revascularization Is associated with a reduced stroke risk in patients with sickle cell-associated moyamoya syndrome. Neurosurgery 90:441–446. https://doi.org/10.1227/NEU.0000000000001847

Jang DK, Lee KS, Rha HK, Huh PW, Yang JH, Park IS et al (2017) Bypass surgery versus medical treatment for symptomatic moyamoya disease in adults. J Neurosurg 127:492–502. https://doi.org/10.3171/2016.8.JNS152875

HCUP-US KID Overview n.d. https://hcup-us.ahrq.gov/kidoverview.jsp. Accessed Feb 22, 2024

Raygor KP, Phelps RRL, Rutledge C, Raper DMS, Molinaro A, Fox CK et al (2022) Socioeconomic factors associated with pediatric moyamoya disease hospitalizations: a nationwide cross-sectional study. J Neurosurg Pediatr 2022:1–10. https://doi.org/10.3171/2022.1.PEDS21339

Elixhauser Comorbidity Software, Version 3.7 n.d. https://www.hcup-us.ahrq.gov/toolssoftware/comorbidity/comorbidity.jsp. Accessed Oct 28, 2021

Osorio RC, Raygor KP, Abla AA (2022) Development of a customised programme to standardise comorbidity diagnosis codes in a large-scale database. BMJ Health Care Inform 29:e100532. https://doi.org/10.1136/bmjhci-2021-100532

Ravindra VM, Karsy M, Lanpher A, Bollo RJ, Griauzde J, Scott RM et al (2019) A national analysis of 9655 pediatric cerebrovascular malformations: effect of hospital volume on outcomes. J Neurosurg Pediatr 2019:1–10. https://doi.org/10.3171/2019.5.PEDS19155

Titsworth WL, Scott RM, Smith ER (2016) National analysis of 2454 pediatric moyamoya admissions and the effect of hospital volume on outcomes. Stroke 47:1303–1311. https://doi.org/10.1161/STROKEAHA.115.012168

Khoury RA, Musallam KM, Mroueh S, Abboud MR (2011) Pulmonary complications of sickle cell disease. 35:625–35. https://doi.org/10.3109/03630269.2011.621149

Siddiqui AK, Ahmed S (2003) Pulmonary manifestations of sickle cell disease. Postgrad Med J 79:384–390. https://doi.org/10.1136/PMJ.79.933.384

Miller AC, Gladwin MT (2012) Pulmonary complications of sickle cell disease. Am J Respir Crit Care Med 185:1154–1165. https://doi.org/10.1164/rccm.201111-2082CI

Klings ES, Wyszynski DF, Nolan VG, Steinberg MH (2006) Abnormal pulmonary function in adults with sickle cell anemia. Am J Respir Crit Care Med 173:1264–1269. https://doi.org/10.1164/RCCM.200601-125OC

Platt OS, Brambilla DJ, Rosse WF, Milner PF, Castro O, Steinberg MH et al (1994) Mortality in sickle cell disease. Life expectancy and risk factors for early death. New England J Med 330:1639–1644. https://doi.org/10.1056/NEJM199406093302303

Mutiso VM, Ongaro N (2006) Sickle cell disease in surgery. Tropical Doctor 2006:200–202

Lu Y, Lin CC, Doermann A, Patel N, Bhatia NN, Kiester PD et al (2019) Impact of sickle cell anemia on inpatient morbidity after spinal fusion. Clinical Spine Surgery 32:439–443. https://doi.org/10.1097/BSD.0000000000000819

Xu R, Xie ME, Khalifeh J, Feghali J, Yang W, Kim J et al (2022) Timing of revascularization in ischemic moyamoya disease: association of early versus delayed surgery with perioperative and long-term outcomes. World Neurosurg 166:e721–e730. https://doi.org/10.1016/j.wneu.2022.07.090

Xu R, Xie ME, Feghali J, Yang W, Kim J, Lee R et al (2022) Revascularization of hemorrhagic moyamoya disease in a North American cohort: the role of timing in perioperative and long-term outcomes. Neurosurgery 90:434–440. https://doi.org/10.1227/NEU.0000000000001850

Kokotailo RA, Hill MD (2005) Coding of stroke and stroke risk factors using international classification of diseases, revisions 9 and 10. Stroke 36:1776–1781. https://doi.org/10.1161/01.STR.0000174293.17959.a1

Tirschwell DL, Longstreth WT (2002) Validating administrative data in stroke research. Stroke 33:2465–2470. https://doi.org/10.1161/01.str.0000032240.28636.bd

Berman MF, Stapf C, Sciacca RR, Young WL (2002) Use of ICD-9 coding for estimating the occurrence of cerebrovascular malformations. AJNR Am J Neuroradiol 23:700–705